Skip to main content

Effect of pectin, lecithin, and antacid feed supplements (Egusin®) on gastric ulcer scores, gastric fluid pH and blood gas values in horses



The objectives of this study were to evaluate the effects of two commercial feed supplements, Egusin 250® [E-250] and Egusin SLH® [E-SLH], on gastric ulcer scores, gastric fluid pH, and blood gas values in stall-confined horses undergoing feed-deprivation.


Nine Thoroughbred horses were used in a three-period crossover study. For the three treatment groups, sweet feed was mixed with E-250, E-SLH, or nothing (control group) and fed twice daily. Horses were treated for 21 days, then an additional 7 days while on an alternating feed-deprivation model to induce or worsen ulcers (period one). In periods two and three, horses (n=6) were treated for an additional 7 days after feed-deprivation. Gastroscopies were performed on day -1 (n=9), day 21 (n=9), day 28 (n=9) and day 35 (n=6). Gastric juice pH was measured and gastric ulcer scores were assigned. Venous blood gas values were also measured.


Gastric ulcers in control horses significantly decreased after 21 days, but there was no difference in ulcer scores when compared to the Egusin® treated horses. NG gastric ulcer scores significantly increased in E-250 and control horses on day 28 compared to day 21 as a result of intermittent feed-deprivation, but no treatment effect was observed. NG ulcer scores remained high in the control group but significantly decreased in the E-SLH- and E-250-treated horses by day 35. Gastric juice pH values were low and variable and no treatment effect was observed. Mean blood pCO2 values were significantly increased two hours after feeding in treated horses compared to controls, whereas mean blood TCO2 values increased in the 24 hour sample, but did not exceed 38 mmol/l.


The feed-deprivation model increased NG gastric ulcer severity in the horses. However, by day 35, Egusin® treated horses had less severe NG gastric ulcers compared to untreated control horses. After 35 days, Egusin® products tested here ameliorate the severity of gastric ulcers in stall-confined horses after feed stress.


Nonglandular (NG) gastric ulcers, as part of the equine gastric ulcer syndrome (EGUS), are common in performance horses, and the current FDA-approved pharmaceutical agent in the United States, omeprazole (GastroGard® paste, Merial Limited, Decatur, GA, USA), is effective in treatment [116]. However, pharmaceutical agents are expensive, require a prescription, must be administered orally, and gastric ulcer recurrence is common once treatment is discontinued [1517]. Development of a less expensive and natural alternative that could be added to the feed would be desirable.

Recently, there has been increased interest in the use of feed supplements to treat and prevent gastric ulcers in horses, and many commercial products are available [1820]; however, little data exists on the efficacy of these supplements. Two such commercially available feed supplements containing dried apple pectin pulp and other fruit products, lecithin, sodium bicarbonate, calcium bicarbonate, dehydrated alfalfa meal, insoluble oat fiber (ß-glucan), polar lipids, and natural antioxidants (Egusin 250® (E-250) and Egusin SLH® (E-SLH), Centaur Animal Health, Overland Park, KS, USA) are commercially available as aids in promoting a healthy stomach and as aids in preventing the destruction of the stomach lining (manufacturer claim) [21]. Several ingredients in these feed supplements been shown in other species to support and protect the stomach lining, support normal digestive function, bind bile acids, and protect the stomach against the generation of damaging oxygen free radicals [19, 20, 2226]. In addition, antacids like calcium carbonate have been shown to protect the nonglandular (NG) mucosa in vitro from the damaging effects gastric acids [27, 28]; however, there are no critical studies on the use of this commercial supplements in horses.

The purpose of this study was to evaluate the effect of E-SLH powder and E-250 pellets on NG gastric ulcer scores, gastric juice pH, and blood gas values in stall-confined horses undergoing feed deprivation. We hypothesize that E-SLH- and E-250-treated horses will have less severe NG gastric ulcers, higher gastric juice pH, and similar blood gas values compared to untreated control horses.


All procedures were approved by the Louisiana State University (LSU) Institutional Animal Care and Use Committee (LSU IACUC Protocol #10-078). All horses used in the study were Thoroughbred or Thoroughbred-cross breeds (n=9; 4-11 years of age, 5 geldings & 4 mares, 429-593 kg body weight) from the resident Equine Health Studies Program (EHSP) herd at LSU School of Veterinary Medicine. The study was performed in the fall and winter, from September 23, 2010 through February 15, 2011. Before the beginning of the study, a physical examination was performed on all horses in order to exclude presence of clinical disease. All horses were vaccinated in the spring for Eastern Equine Encephalitis, Western Equine Encephalitis, West Nile Virus Encephalitis, Tetanus, and Influenza and dewormed with a product containing ivermectin or moxidectin (200 μg/kg body weight, orally, twice yearly) as part of the routine herd care. For period 1 of the study, horses enrolled were stratified by equine gastric ulcer syndrome (EGUS) score [15] as recorded on day -1, after gastroscopy examination, and then randomly assigned to one of three treatment groups (three horses per treatment group) by drawing numbers out of a hat: control (untreated), E-250 (125 gm, top-dressed on sweet feed, twice daily) and E-SLH (50 gm, top-dressed on sweet feed, twice daily). For period 2, horses were randomly assigned to the alternate two treatment groups (three horses per treatment group) by drawing a number out of a hat. For period 3, horses were assigned to the treatment groups (three horses per treatment group) that they had not been assigned to previously. The treatment groups were equal (n=3) for all the treatment periods, including periods 2 and 3.

The experiment was performed as a three-period, three-treatment crossover design. Horses were housed in stalls and fed sweet feed (1 kg, twice daily, Omolene 100, Purina Mills, St. Louis, MO, USA). Horses were also fed mixed grass hay (1.5% of body weight) divided into two equal feedings per day. Horses served as their own controls.

The day prior to the beginning of each period (Day-1), horses were taken out of the pasture and housed in non-environmentally controlled 3 m x 3 m stalls. Horses in the treatment groups received E-250 or E-SLH top-dressed on sweet feed twice daily during treatment periods, while control horses received the same amount of sweet feed without supplement added. At the end of 21 days of treatment, horses were subjected to a modified intermittent feed-deprivation protocol to cause or worsen existing NG gastric ulcers [29]. Briefly, during the feed-deprivation periods, horses were muzzled and deprived of feed for 24 hours, then fed their normal ration for 24 hours until a total of 96 hours of cumulative feed-deprivation was achieved. Horses were muzzled and wood-shavings were removed from the stalls during the feed-deprivation period to prevent ingestion of bedding and manure. E-250 and E-SLH-treated horses continued to receive treatment twice daily top-dressed on sweet feed, while control horses received the same amount of sweet feed without treatment. After each period, horses were turned out in the pasture, where they were maintained on native grass pastures supplemented with native round-bale grass hay for at least 2 weeks to prevent carry-over treatment effects. Period 1 was 28 days in length and periods 2 and 3 were 35 days in length. Periods 2 and 3 were lengthened to determine the effect of treatment on recovery from the feed-deprivation model, and each treatment group continued to have three horses. In addition, a longer treatment for periods 2 and 3 was added, as a previous study in horses treated with pectin and lecithin did not show a treatment effect until after being treated for 30 days [20]. Horses had free access to water at all times. After period 3 horses were returned to the EHSP herd.

Gastroscopy was performed on all horses on days -1, 21, and 28 of treatment in period 1, and on days -1, 21, 28, and 35 of treatment in periods 2 and 3. Gastroscopic examination was performed using a 3-m endoscope (Karl Storz, El Segundo, CA, USA). To improve visualization of the stomach, feed was withheld for 16-18 hours and water for 3-4 hours prior to gastroscopy. Horses were sedated with xylazine (0.4 mg/kg, IV; AnaSed®, Lloyd, Shenandoah, IA, USA) prior to gastroscopic examination. To enable observation of the NG squamous mucosa (fundus ventriculi), margo plicatus, and glandular mucosa (corpus ventriculi), the stomach was insufflated with air using an air compressor (Airhead® High Pressure Air Pump, Kwik Tek, Denver, CO, USA) attached to the endoscope biopsy channel until the rugae, or stomach folds, disappeared. The mucosa was rinsed of adherent food material and mucus with tap water flushed through the endoscope biopsy channel. Each horse’s stomach was assigned an EGUS gastric ulcer score by one of the authors (FMA) masked to treatment groups, based on the EGUS ulcer scoring system where, score 0 = Intact mucosa (can have reddening and/or hyperkeratosis), score 1 = small single or small multifocal ulcers, score 2 is large single or large multifocal ulcers, and score 3 = extensive (often coalescing) ulcers with areas of apparent deep ulceration [15]. In addition, glandular ulcers were counted and recorded.

Gastric fluid was aspirated through the biopsy channel of the endoscope prior to insufflation of the stomach or addition of tap water and pH was measured within 30 minutes using a benchtop pH meter (ThermoOrion pH Meter Model 410A, Thermo Fisher Scientific, Beverly, MA).

Venous blood samples were collected from the jugular vein in heparinized blood gas syringes (Arterial Blood Sampler, Radiometer Medical ApS, Brøshøj, Denmark), air bubbles were expressed, the needle removed and syringe capped, and immediately placed in ice. The blood gas samples were obtained from all horses on the first three days of treatment Periods 1 and 3. Samples were collected prior to treatment and 2, 6, 12 (before the second treatment), 24 (before the third treatment), and 48 hours (before the fourth treatment) after treatment. These samples were analyzed using an automated blood gas analyzer (Rapidpoint 405, Siemens, Norwood, MA) for bicarbonate concentration ([HCO3]), total carbon dioxide (TCO2) and partial pressure of carbon dioxide (pCO2).

Data were pooled and means and standard error of the means (SEM) were reported on all variables using the 35-day values taken from horses completing periods 2 and 3. Data were analyzed statistically using a statistical analysis package for personal computers (SAS® 9.1, SAS Institute, Inc., Cary, NC). A repeated measures analysis of variance (ANOVA) using a mixed effects model (proc MIXED) was used to analyze the data. Fixed effects in the model included Treatment, Period and the interaction of Treatment*Period. When significant differences were found, post-hoc pairwise comparisons were conducted with t-tests of least-squares means for main effects and for interaction effects. Significant was set at P < 0.05.


Physical examinations were within normal limits and there was no evidence of clinical gastrointestinal disease in any of the horses prior to enrollment in the study. One horse entered the trial with a laceration over the metacarpal III bone. This wound was routinely cleaned and bandaged throughout the course of the study and no medication was administered for the wound. Feed quantities (hay) were adjusted so that body weight did not change significantly during the trial. The amount of hay required to maintain body weight was not evaluated statistically.

E-250, a pelleted formulation, when mixed with sweet feed, was readily consumed by all horses. E-SLH, a powder formulation, when mixed with sweet feed, was consumed by all horses, but some horses took several hours to consume the product and the powder immediately sifted to the bottom of the grain bucket when top-dressed.

One untreated horse and one E-250-treated horse developed abdominal pain (colic) during period 1 and the final day of period 3 of the study, respectively. In both of these horses, clinical signs resolved with flunixin meglumine (1.1 mg/kg, IV, once) and mineral oil (2 liters, via nasogastric tube) administration.

A period effect was not noted.

Gastric ulcer scores

There was no significant difference in mean EGUS scores between treatment groups on day 1, prior to beginning the study. However, mean EGUS scores decreased significantly (p<0.05) in the control group after 21 days of treatment, when compared to day 1, but there was no difference in ulcer scores when compared to the Egusin® treated horses on day 21. On day 28 of treatment, mean EGUS scores significantly increased in the control and E-250 groups, indicating that the feed-deprivation model was effective in inducing or worsening gastric ulcers. In addition, mean gastric ulcer scores did not significantly increase in the Egusin SLH®-treated horses at day 28 when compared to day 21. However, there was no treatment effect at this time point. By day 35 of treatment, one week after the feed-deprivation period, mean EGUS scores significantly decreased in the E-SLH- and E-250-treated horses, when compared to untreated controls at the same time point and scores on day 28 of the same treatment group. Also, by day 35 of treatment, individual EGUS scores either decreased or stayed the same in all Egusin®-treated horses (Figure 1).

Figure 1
figure 1

Gastric ulcer scores Mean ± SEM of Equine Gastric Ulcer Syndrome (EGUS) scores in horses fed Egusin 250® Supplement, Egusin SLH® Supplement, and controls during periods two and three before treatment (Day -1), after 21 days of treatment (Day 21), after 28 days of treatment (Day 28), and after 35 days of treatment (Day 35). A 7-day alternating feed-deprivation protocol was employed between Days 21 and 28. † Denotes a significant (P < 0.05) difference from scores from the previous week within a group and * denotes significant differences (P < 0.05) from control values for the same week. (controls = red bar; E-250 = yellow bar; E-SLH = blue bar)

Glandular ulcers

Glandular ulcers were observed in 6/72 (8%) gastroscopic examinations performed in this study. There was no significant day or day by treatment effect on the number of glandular ulcers in this study.

Gastric fluid pH

Mean ± SEM gastric fluid pH, 2.76 ± 1.53 (range, 1.39-8.0), aspirated just prior to gastroscopic examination, was low and variable in horses in this study. There was no significant day or treatment effect on gastric juice pH during the study period. On the mornings of evaluation, the E-250 and E-SLH were not fed on the mornings until after the horses underwent gastroscopy.

Blood gas values

[HCO3] did not significantly differ between days or within treatment groups for the study. However, mean pCO2 significantly increased 2 hours after initial treatment on day 0 in both E-250- and E-SLH-treated horses, when compared the untreated controls (Figure 2). Mean TCO2 was significantly higher in the E-250- and E-SLH-treated horses, 24 hours after treatment when compared to the 12-hour samples (Figure 3). However, mean TCO2 did not differ significantly from controls or between treatment groups throughout the rest of the treatment period (Figure 3).

Figure 2
figure 2

Partial Pressure of CO 2 Mean partial pressure of CO2 (pCO2) + SEM in whole heparinized venous blood in control, Egusin 250®, and Egusin SLH® treated horses before treatment (0), 2, 6, 12, 24, and 48 hours after treatment. * denotes a significant (P < 0.05) difference from control values at the same time point. (controls = red line with diamonds; E-250 = yellow line with squares; E-SLH = blue line with triangles)

Figure 3
figure 3

Total CO 2 Mean total CO2 (TCO2) + SEM in whole heparinized venous blood in control, Egusin 250®, and Egusin SLH® treated horses before treatment (0), 2, 6, 12, 24, and 48 hours after treatment. (†) denotes a significant (P < 0.05) difference in measurement from the previous time within a group. (controls = red line with diamonds; E-250 = yellow line with squares; E-SLH = blue line with triangles)


The Egusin® products, when mixed with sweet feed, were consumed by all horses. However, the E-250 (pellet formulation) was consumed more readily and completely than the E-SLH (powder formulation). The E-SLH sifted to the bottom of the feed tub and took longer for the horses to consume.

Two horses, an untreated control and E-250-treated horse, had signs of abdominal pain (colic) during the study. These horses were treated medically and recovered completely. Abdominal pain is a common clinical sign of gastric ulcers in horses and may have caused the signs seen in these two horses as they both had ulcers in the study. Although mineral oil and flunixin meglumine was administered to these two horses during the study, the authors feel that at the single dose administered, the drugs did not interfere with the results. No other clinical signs were noted in horses in this study.

Period one lasted for 28 days, while periods two and three were extended for a further 7 days after the feed-deprivation period (for a total of 35 days). This protocol change was based on a lack of response within the first 28 days, as well as previous studies with products containing pectin and lecithin and other ingredients that demonstrated improved ulcer scores after 30 days of treatment [18, 20]. Thus, a 35-day, was incorporated into the later periods (2 and 3) to allow time to adequately evaluate the effects of treatment. In addition, statistical analysis focused on gastric ulcers scores in the 6 horses in each treatment group for these periods.

The intermittent feed-deprivation model used in this study was successful in worsening existing NG gastric ulcers, as mean EGUS scores significantly increased in the untreated controls and in the E-250-treated group after feed-deprivation. Egusin SLH® treated horses did not show an increase in ulcer severity after feed-deprivation, and at day 28, there was no difference between control group and Egusin® treatments. However, after 35 days of treatment, in control horses, gastric ulcer scores remained similar to day 28, while gastric ulcer scores decreased significantly in both Egusin® -treated groups. Glandular ulcers were only seen in a few horses and there was not treatment effect.

In the study reported here, there was a decrease in mean EGUS gastric ulcer scores in the control horses after 21 days of treatment, but the scores were not significantly different from the other treatment groups at the same time point. Previous studies have shown that pasture-housed horses typically have less severe NG ulcers than stall-confined horses [30]. However, in a recent study, 71% of non-pregnant broodmares housed at pasture had gastric ulcers and some were severe [31]. The exact reason for the decrease in gastric ulcer severity in control horses in the study reported here is unknown, but might have been due to changes in management during this period. Typically, pasture grass in Louisiana has poor nutritional quality during the late fall and winter. The decreased feeding stress and increased nutrition could have led to the decreased severity of gastric ulcers in control horses during the first 21 days of the study compared to day 1. However, a similar decrease was not noted in the other treatment groups. Unfortunately, a feed analysis was not performed during the study period. During the study, horse body weight was measured before each gastroscopic examination and feed intake was adjusted to maintain body weight.

Egusin®-treated horses had improved NG gastric ulcer scores in this study after 35 days. The reason for the improvement in NG gastric ulcer scores might have been due to the ingredients found in the supplements. The Egusin® supplements used in this study contain surface-active and antacid ingredients, of which the amounts are proprietary. Surface-active ingredients include pectin (dried apple pectin pulp), soy lecithin, ß-glutan (micro-milled whole oats), whereas the antacids include dehydrated alfalfa meal, calcium carbonate, and sodium bicarbonate.

Pectin is a soluble complex polysaccharide derived from the cell wall of fruits and vegetables. Lecithin is a phospholipid derived from soybeans and is an emulsifying, lubricating agent that has surfactant properties. Pectin acts with lecithin to form a hydrophobic barrier on the gastric mucosal membranes, protecting them against the corrosive effects of gastric acids. In horses, the surface of the NG stomach is coated with dense osmophilic surface-active phospholipids (SAPLs), similar to the structure of pulmonary surfactant [32]. These hydrophobic SAPLs might provide the primary defense mechanism against exposure to hydrochloric and other organic acids found in gastric fluid. Feed additives containing pectin and lecithin have been previously evaluated in horses with gastric ulcers and the results have been mixed [19, 20, 33]. Egusin® (which contains a proprietary mixture of pectin and lecithin) treatment significantly decreased NG gastric ulcer severity, when compared to untreated control horses, but there was not a treatment effect until day 35. In two previous studies, pectin and lecithin containing supplements decreased NG gastric ulcer severity after 10 days [33] and after 30 days [20] of treatment. Results in the later study, where horses were fed for 30 days, were similar to data in the study presented here, where it took 35 days to see a treatment effect in the Egusin®-treated horses.

However in another study, pectin and lecithin-treatment failed to prevent NG gastric ulcers from worsening after a 96-hour feed-deprivation period [19]. The results from that study were similar to the results from the study presented here, where Egusin 250® treatment failed to prevent NG gastric ulcers from worsening during the feed-deprivation period[19]. However, E-SLH prevented the worsening of NG gastric ulcers during the period of feed-deprivation, but there was no treatment effect at day 28, when Egusin SLH® was compared to the other treatment groups. Therefore the results should not be over interpreted as a response to treatment. It should be noted, however, that Egusin SLH® has a higher concentration of pectin and lecithin and other ingredients than Egusin 250®, which could have accounted for this effect.

In addition to surface acting phospholipid compounds, Egusin® products contain buffering agents, including calcium carbonate and sodium bicarbonate, which are commonly used used in people and horses to buffer stomach contents and neutralize gastric juice pH. No studies have critically evaluated the effects of antacids on gastric ulcer scores in horses. However, calcium carbonate reversed the damaging effects of hydrochloric acid on sodium and chloride transport across the NG mucosa in an in vitro Ussing chamber model [27, 28]. In addition, one of the authors (FMA) showed that a supplement (Neigh-Lox®, Kentucky Performance Products, LLC, Versailles, KY) containing calcium carbonate fed to horses for 30 days increased gastric juice pH for 2 hours after feeding, but failed to improve gastric ulcer scores (unpublished data, Frank M. Andrews). This is similar to previous studies where antacids increase gastric juice pH for approximately 2 hours after administration [34]. Unfortunately, gastric juice pH was not measured two hours after feeding in the horses in the study. In addition to calcium carbonate, Egusin® also contains sodium bicarbonate, which is not commonly used to treat gastric ulcers in horses and has not been critically evaluated for that purpose. However, it may increase gastric juice pH. In addition, sodium bicarbonate, when fed orally, can effect on blood pH. Sodium bicarbonate “milkshakes” have been generally speculated to help racing horses by increasing the pH of the blood, buffering lactic acid, and delaying onset of fatigue in muscles [35]. The generally accepted level of TCO2 in Thoroughbred racing in the United States is below 37 mmol/l [36]. Values that exceed 37 mmol/l are considered doping. The mean TCO2 values in the horses in this study did not exceed 37 mmol/l, despite the presence of calcium carbonate and sodium bicarbonate in the supplements. However, it is unlikely that the sodium bicarbonate concentration found in the Egusin® products exceeds 0.5 g/kg, which has been shown to cause the blood TCO2 to increase above doping values.

The other ingredient that might have provided some buffering capacity is dried alfalfa meal. Although there are no studies evaluating the use of dried alfalfa meal in horses with gastric ulcers, horses fed alfalfa hay had higher gastric juice pH and lower NG gastric ulcer scores than the same horses fed bromegrass hay [37]. In another study, horses exercised and fed alfalfa hay had less severe NG gastric ulcers than horse that were fed grass hay [38]. It was hypothesized that the calcium carbonate in the alfalfa hay buffered stomach acid or directly inhibited gastric acid secretion as has been shown in rats fed diets containing 2% calcium carbonate [38]. It is unlikely that the concentration of calcium carbonate found in the dried alfalfa meal found in Egusin® would be equivalent to that found in baled alfalfa hay, therefore its effect is likely minimal.

Gastric fluid pH was generally low and variable but not significantly different in Egusin® treated horses when compared to untreated controls. Gastric fluid pH can be affected by stomach contents and the location in which the sample was taken [39]. A single sample aspirated from the stomach of horses can be variable and might not as accurate as continuous monitoring with a pH probe. However, gastric juice pH in the study reported here was similar to measurements where samples were collected via gastric cannulae and by continuous monitoring [18, 37, 40]. Neither Egusin® product significantly altered gastric fluid pH at the times measured. However, perhaps a significant difference might have been seen if sampling would have been obtained within 2 hours of treatment, but may not have had a significant effect on gastric ulcer healing.

Other nutritional ingredients found in these Egusin® products may have decreased NG gastric ulcer scores in these horses. ß-glucan has been shown to form gels in the stomach of other species and acts to coat the stomach lining. Studies in rats have shown antiulcergenic effects of ß-(1-->3)-glucosyl-linkage on beta-1-->3)-glucan itself is an important part of the active principle for anti-ulcerogenesis [41]. Studies on the effects of ß-glucan have not been reported in horses, but may be similar to those seen in rats. Also, the polar lipids in these supplements are a rich source of phospholipids and aid in re-establishing the stomach lining. However, there are no studies reported in horses on the effect of polar lipids on gastric ulcer scores in horses.


The results of this study confirm that stall-confined horses undergoing feed-deprivation have a significant increase in the severity of NG gastric ulcers. However, it should be noted that a change in management from pasture to stall confinement and regular feeding could lower NG gastric ulcer scores in horses. Control horses had significantly decreased gastric ulcer scores after 21 days of stall-confinement, but these values were not different from the other treatment groups. Based on the data reported here, it appears that the ingredients contained in Egusin 250® were not effective in reducing gastric ulcer severity during feed-deprivation, whereas the similar ingredients in Egusin SLH®, which are higher in concentration than Egusin 250®, may have aided in blunting an increase in NG gastric severity during feed-deprivation, although gastric ulcer scores increased in all treatment groups. Futhermore, gastric ulcer scores decreased in both Egusin® -treated groups after 35 days of feeding (7 days after feed-deprivation). Thus, Egusin® supplements fed twice daily for 35 days might reduce gastric ulcers scores after feed stress without exceeding threshold concentrations of bicarbonate.



equine gastric ulcer syndrome


Egusin 250®


Egusin SLH®




bicarbonate concentration


total carbon dioxide


partial pressure of carbon dioxide


standard error of the mean


surface-active phospholipids


  1. MacAllister CG, Sifferman RL, McClure SR, White GW, Vatistas NJ, Holste JE, Ericcson GF, Cox JL: Effects of omeprazole paste on healing of spontaneous gastric ulcers in horses and foals: a field trial. Equine Veterinary Journal Supplement. 1999, 77-80.

    Google Scholar 

  2. Vatistas NJ, Sifferman RL, Holste J, Cox JL, Pinalto G, Schultz KT: Induction and maintenance of gastric ulceration in horses in simulated race training. Equine Veterinary Journal Supplement. 1999, 40-44.

    Google Scholar 

  3. Sandin A, Skidell J, Haggstrom J, Nilsson G: Postmortem findings of gastric ulcers in Swedish horses older than age one year: a retrospective study of 3715 horses (1924-1996). Equine veterinary journal. 2000, 32: 36-42. 10.2746/042516400777612044.

    Article  CAS  PubMed  Google Scholar 

  4. Begg LM, O'Sullivan CB: The prevalence and distribution of gastric ulceration in 345 racehorses. Australian veterinary journal. 2003, 81: 199-201. 10.1111/j.1751-0813.2003.tb11469.x.

    Article  CAS  PubMed  Google Scholar 

  5. Dionne RM, Vrins A, Doucet MY, Pare J: Gastric ulcers in standardbred racehorses: prevalence, lesion description, and risk factors. Journal of Veterinary Internal Medicine. 2003, 17: 218-222. 10.1111/j.1939-1676.2003.tb02437.x.

    Article  PubMed  Google Scholar 

  6. Rabuffo TS, Orsini JA, Sullivan E, Engiles J, Norman T, Boston R: Associations between age or sex and prevalence of gastric ulceration in Standardbred racehorses in training. Journal of the American Veterinary Medical Association. 2002, 221: 1156-1159. 10.2460/javma.2002.221.1156.

    Article  PubMed  Google Scholar 

  7. Nieto JE, Snyder JR, Beldomenico P, Aleman M, Kerr JW, Spier SJ: Prevalence of gastric ulcers in endurance horses--a preliminary report. Veterinary journal. 2004, 167: 33-37. 10.1016/j.tvjl.2003.09.005.

    Article  Google Scholar 

  8. Bezdekova B, J P, Vyskocil M, Plachy J: Prevalence of equine gastric ulceration in Standardbred racehorses in Czech Republic. Acta Veterinaria Brno. 2005, 74: 59-65. 10.2754/avb200574010059.

    Article  Google Scholar 

  9. Bezdekova B, J P, Vyskocil M, Plachy J: Gastric ulceration and exercise intensity in Standardbred racehorses in Czech Republic. Acta Veterinaria Brno. 2005, 74: 67-71. 10.2754/avb200574010067.

    Article  Google Scholar 

  10. Bezdekova B, J P, Vyskocil M: Pathomorphological study on gastroduodenal ulceration in horses: localization of lesions. Acta Veterinaria Hungarica. 2007, 55: 241-249. 10.1556/AVet.55.2007.2.10.

    Article  PubMed  Google Scholar 

  11. Roy MA, Vrins A, Beauchamp G, Doucet MY: Prevalence of ulcers of the squamous gastric mucosa in standardbred horses. Journal of Veterinary Internal Medicine. 2005, 19: 744-750. 10.1111/j.1939-1676.2005.tb02755.x.

    Article  PubMed  Google Scholar 

  12. Chameroy KA, N J, Bushmick SL, Dinger JE, Hoagland TA, Saxton AM: Prevalence of non-glandular gastric ulcers in horses involved in a university riding program. Journal of Equine Veterinary Science. 2006, 26: 207-211. 10.1016/j.jevs.2006.03.001.

    Article  Google Scholar 

  13. Jonsson H, Egenvall A: Prevalence of gastric ulceration in Swedish Standardbreds in race training. Equine veterinary journal. 2006, 38: 209-213.

    Article  CAS  PubMed  Google Scholar 

  14. Moghaddam G, H A, Nadalian MG, Mokhberdezfhli MR: A survey of risk factors for gastric ulceration in the Caspian Horses in Iran. Journal of Animal and Veterinary Advances. 2008, 7: 173-177.

    Google Scholar 

  15. Andrews FM, Sifferman RL, Bernard W, Hughes FE, Holste JE, Daurio CP, Alva R, Cox JL: Efficacy of omeprazole paste in the treatment and prevention of gastric ulcers in horses. Equine Veterinary Journal Supplement. 1999, 81-86.

    Google Scholar 

  16. Murray MJ, Haven ML, Eichorn ES, Zhang D, Eagleson J, Hickey GJ: Effects of omeprazole on healing of naturally-occurring gastric ulcers in thoroughbred racehorses. Equine veterinary journal. 1997, 29: 425-429. 10.1111/j.2042-3306.1997.tb03153.x.

    Article  CAS  PubMed  Google Scholar 

  17. Furr MO, M M: Treatment of gastric ulcers in horses with histamine type 2 receptor antagonists. Equine Veterinary Journal Supplement. 1989, 7: 77-79.

    Article  PubMed  Google Scholar 

  18. Huff NK, Auer AD, Garza F, Keowen ML, Kearney MT, McMullin RB, Andrews FM: Effect of sea buckthorn berries and pulp in a liquid emulsion on gastric ulcer scores and gastric juice pH in horses. Journal of Veterinary Internal Medicine. 2012, 26: 1186-1191. 10.1111/j.1939-1676.2012.00975.x.

    Article  CAS  PubMed  Google Scholar 

  19. Murray MJ, Grady TC: The effect of a pectin-lecithin complex on prevention of gastric mucosal lesions induced by feed deprivation in ponies. Equine veterinary journal. 2002, 34: 195-198.

    Article  CAS  PubMed  Google Scholar 

  20. Venner M, Lauffs S, Deegen E: Treatment of gastric lesions in horses with pectin-lecithin complex. Equine Veterinary Journal Supplement. 1999, 91-96.

    Google Scholar 

  21. Centaur Animal Health. []

  22. Goddard PJ, Kao YC, Lichtenberger LM: Luminal surface hydrophobicity of canine gastric mucosa is dependent on a surface mucous gel. Gastroenterology. 1990, 98: 361-370.

    CAS  PubMed  Google Scholar 

  23. Lichtenberger LM, Graziani LA, Dial EJ, Butler BD, Hills BA: Role of surface-active phospholipids in gastric cytoprotection. Science. 1983, 219: 1327-1329. 10.1126/science.6828859.

    Article  CAS  PubMed  Google Scholar 

  24. Hills BA, Kirwood CA: Surfactant approach to the gastric mucosal barrier: protection of rats by banana even when acidified. Gastroenterology. 1989, 97: 294-303.

    CAS  PubMed  Google Scholar 

  25. Swarm RA, Ashley SW, Soybel DI, Ordway FS, Cheung LY: Protective effect of exogenous phospholipid on aspirin-induced gastric mucosal injury. American journal of surgery. 1987, 153: 48-53. 10.1016/0002-9610(87)90200-5.

    Article  CAS  PubMed  Google Scholar 

  26. Hills BA: Gastric surfactant and the hydrophobic mucosal barrier. Gut. 1996, 39: 621-624. 10.1136/gut.39.5.621.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Nadeau JA, Andrews FM, Patton CS, Argenzio RA, Mathew AG, Saxton AM: Effects of hydrochloric, valeric, and other volatile fatty acids on pathogenesis of ulcers in the nonglandular portion of the stomach of horses. American journal of veterinary research. 2003, 64: 413-417. 10.2460/ajvr.2003.64.413.

    Article  CAS  PubMed  Google Scholar 

  28. Nadeau JA, Andrews FM, Patton CS, Argenzio RA, Mathew AG, Saxton AM: Effects of hydrochloric, acetic, butyric, and propionic acids on pathogenesis of ulcers in the nonglandular portion of the stomach of horses. American journal of veterinary research. 2003, 64: 404-412. 10.2460/ajvr.2003.64.404.

    Article  CAS  PubMed  Google Scholar 

  29. Murray MJ, Eichorn ES: Effects of intermittent feed deprivation, intermittent feed deprivation with ranitidine administration, and stall confinement with ad libitum access to hay on gastric ulceration in horses. American journal of veterinary research. 1996, 57: 1599-1603.

    CAS  PubMed  Google Scholar 

  30. Feige K, Furst A, Eser MW: [Effects of housing, feeding and use on equine health with emphasis on respiratory and gastrointestinal diseases]. Schweizer Archiv fur Tierheilkunde. 2002, 144: 348-355. 10.1024/0036-7281.144.7.348.

    Article  CAS  PubMed  Google Scholar 

  31. le Jeune SS, Nieto JE, Dechant JE, Snyder JR: Prevalence of gastric ulcers in Thoroughbred broodmares in pasture: a preliminary report. Veterinary journal. 2009, 181: 251-255. 10.1016/j.tvjl.2008.03.020.

    Article  Google Scholar 

  32. Ethell MT, Hodgson DR, Hills BA: Evidence for surfactant contributing to the gastric mucosal barrier of the horse. Equine veterinary journal. 2000, 32: 470-474.

    Article  CAS  PubMed  Google Scholar 

  33. Ferrucci F, Zucca E, Croci C, Di Fabio V, Ferro E: Treatment of gastric ulceration in 10 standardbred racehorses with a pectin-lecithin complex. Veterinary Record. 2003, 152: 679-681. 10.1136/vr.152.22.679.

    Article  CAS  PubMed  Google Scholar 

  34. Clark CK, Merritt AM, Burrow JA, Steible CK: Effect of aluminum hydroxide/magnesium hydroxide antacid and bismuth subsalicylate on gastric pH in horses. Journal of the American Veterinary Medical Association. 1996, 208: 1687-1691.

    PubMed  Google Scholar 

  35. Williams RB: Sodium bicarbonate loading and the rules of racing. British Veterinary Journal. 1995, 151: 473-475. 10.1016/S0007-1935(05)80021-1.

    Article  CAS  PubMed  Google Scholar 

  36. Auer DE, Skelton KV, Tay S, Baldock FC: Detection of bicarbonate administration (milkshake) in standardbred horses. Australian veterinary journal. 1993, 70: 336-340. 10.1111/j.1751-0813.1993.tb00879.x.

    Article  CAS  PubMed  Google Scholar 

  37. Nadeau JA, Andrews FM, Mathew AG, Argenzio RA, Blackford JT, Sohtell M, Saxton AM: Evaluation of diet as a cause of gastric ulcers in horses. American journal of veterinary research. 2000, 61: 784-790. 10.2460/ajvr.2000.61.784.

    Article  CAS  PubMed  Google Scholar 

  38. Lybbert T, G P, Cohen N, Scott B, Sigler D: Feeding alfalfa hay to exercising horses reduces the severity of gastric squamous mucosal ulceration. Annual Meeting of the American Association of Equine Practitioners; Orlando, Florida. 2007.

    Google Scholar 

  39. Murray MJ, Grodinsky C: Regional gastric pH measurement in horses and foals. Equine veterinary journal Supplement. 1988, 73-76.

    Google Scholar 

  40. Murray MJ, Schusser GF: Measurement of 24-h gastric pH using an indwelling pH electrode in horses unfed, fed and treated with ranitidine. Equine Veterianry Journal. 1993, 25: 417-421. 10.1111/j.2042-3306.1993.tb02983.x.

    Article  CAS  Google Scholar 

  41. Yoshizawa M, Yokoyama K, Nakano Y, Nakamura H: Protective effects of barley and its hydrolysates on gastric stress ulcer in rats. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2004, 124: 571-575. 10.1248/yakushi.124.571.

    Article  CAS  PubMed  Google Scholar 

Download references


This article has been published as part of BMC Veterinary Research Volume 10 Supplement 1, 2014: Selected articles from the Eleventh International Equine Colic Research Symposium. The full contents of the supplement are available online at of this supplement has been funded by The British Equine Veterinary Association.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Frank M Andrews.

Additional information

Competing Interests

The study was funded by a grant from the Equine Health Studies Program, Equine Foundation, Louisiana State University School of Veterinary Medicine. The Egusin SLH® and 250® were supplied by the Centaur Corporation. The authors have no competing interest in the products tested.

Authors’ Contributions

Drs. FMA and MCW contributed to study design. Drs. FMA, MCW, NKH and Mr. FG and Mr. MLK contributed to data collection and study execution. Data analysis was performed by Drs. MCW and MTK. Drs. MCW, MTK, and FMA contributed to data interpretation. Drs. MCW and FMA prepared the manuscript and Dr. NKH, Mr. FG and Mr. MLK contributed to editing and proofing reading of the manuscript.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Woodward, M.C., Huff, N.K., Garza, F. et al. Effect of pectin, lecithin, and antacid feed supplements (Egusin®) on gastric ulcer scores, gastric fluid pH and blood gas values in horses. BMC Vet Res 10 (Suppl 1), S4 (2014).

Download citation

  • Published:

  • DOI: